Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy

Summary: The reliance of many cancers on aerobic glycolysis has stimulated efforts to develop lactate dehydrogenase (LDH) inhibitors. However, despite significant efforts, LDH inhibitors (LDHi) with sufficient specificity and in vivo activity to determine whether LDH is a feasible drug target are la...

Full description

Bibliographic Details
Main Authors: Nobu Oshima, Ryo Ishida, Shun Kishimoto, Kristin Beebe, Jeffrey R. Brender, Kazutoshi Yamamoto, Daniel Urban, Ganesha Rai, Michelle S. Johnson, Gloria Benavides, Giuseppe L. Squadrito, Dan Crooks, Joseph Jackson, Abhinav Joshi, Bryan T. Mott, Jonathan H. Shrimp, Michael A. Moses, Min-Jung Lee, Akira Yuno, Tobie D. Lee, Xin Hu, Tamara Anderson, Donna Kusewitt, Helen H. Hathaway, Ajit Jadhav, Didier Picard, Jane B. Trepel, James B. Mitchell, Gordon M. Stott, William Moore, Anton Simeonov, Larry A. Sklar, Jeffrey P. Norenberg, W. Marston Linehan, David J. Maloney, Chi V. Dang, Alex G. Waterson, Matthew Hall, Victor M. Darley-Usmar, Murali C. Krishna, Leonard M. Neckers
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124720300541